You are here: Industry Insights > mRNA-1273

News List

Moderna to supply six million doses of COVID-19 vaccine to Israel expresspharma
December 07, 2020
The company has already initiated the rolling regulatory review process with the Ministry of Health in Israel.
Moderna applies for regulatory authorisation for COVID-19 vaccine europeanpharmaceuticalreview
December 03, 2020
The company has submitted for Emergency Use Authorization in the US and Conditional Marketing Authorization in Europe for its mRNA-1273 vaccine against COVID-19.
Recipharm Inks Covid-19 Vax Pact with Moderna contractpharma
December 02, 2020
Signs of letter of intent for aseptic fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate (mRNA-1273).
UK to procure additional two million doses of mRNA vaccine against COVID-19 expresspharma
December 01, 2020
Moderna announced a supply agreement with the UK government for an additional two million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, to the United Kingdom beginning in March 2021.
Moderna announces vaccine efficacy of 94.1 per cent, to file for EUA with US FDA expresspharma
December 01, 2020
Primary efficacy analysis of the Phase 3 COVE study of mRNA-1273 involving 30,000 participants included 196 cases of COVID-19, of which 30 cases were severe.
EU secures 80 million doses of Moderna COVID-19 vaccine europeanpharmaceuticalreview
November 30, 2020
The European Commission and Moderna have agreed that the company will supply at least 80 million doses of mRNA-1273, the company’s COVID-19 vaccine candidate.
Lonza Congratulates Moderna on Interim Phase 3 Clinical Trial Data americanpharmaceuticalreview
November 26, 2020
Lonza has released the following statement congratulating Moderna on its recent clinical trial:“We congratulate Moderna on this important milestone, which represents a significant scientific achievement and serves as a testament to Moderna’s commitment ..
EMA begins rolling review of Moderna’s COVID-19 vaccine candidate expresspharma
November 18, 2020
Moderna also announced a supply agreement with the UK government to supply mRNA-1273, if approved for use by MHRA.
Moderna COVID-19 Vaccine Candidate Meets Primary Efficacy Endpoint americanpharmaceuticalreview
November 17, 2020
Moderna announced the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the ...
Swissmedic Begins Rolling Review of Moderna’s mRNA COVID-19 Vax contractpharma
November 16, 2020
Moderna completed enrollment of its Phase 3 COVE study of mRNA-1273 on October 22.

Previous page 1 2 3 4 5 6 Next page